Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
MYD88 L265P is a commonly recurring mutation in patients with Waldenström's macroglobulinemia that can be useful in differentiating WaldenStröm’s macrogalobulinesia and non-IgM LPL from B-cell disorders that have some of the same features. Expand
Ibrutinib in previously treated Waldenström's macroglobulinemia.
Ibrutinib was highly active, associated with durable responses, and safe in pretreated patients with Waldenström's macroglobulinemia, and the effect of MYD88 and CXCR4 mutations on outcomes was investigated. Expand
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
This presentation represents consensus recommendations for the clinicopathological definition of Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the Second International… Expand
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
- N. Mitsiades, C. Mitsiades, +11 authors K. Anderson
- Biology, Medicine
- Proceedings of the National Academy of Sciences…
- 21 October 2002
The molecular sequelae of PS-341 treatment in MM cells are characterized and the rationale for future clinical trials of this promising agent, in combination with conventional and novel therapies, to improve patient outcome in MM is explained. Expand
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Clinical activity of Thal against MM that is refractory to conventional therapy is demonstrated and mechanisms of anti-tumor activity of thalidomide and its potent analogs (immunomodulatory drugs [IMiDs]) are delineated. Expand
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
The CXCR4 and CNA findings were validated in independent expansion cohorts of 147 and 30 WM patients, respectively, and provide a genomic basis for understanding the pathogenesis of WM. Expand
International prognostic scoring system for Waldenstrom macroglobulinemia.
The ISSWM retained its prognostic significance in subgroups defined by age, treatment with alkylating agent, and purine analog, and may provide a means to design risk-adapted studies. Expand
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
Targeted therapies directed against MYD88 and/or CXCR4 signaling may provide a personalized treatment approach to Waldenström macroglobulinemia and impact overall survival in WM. Expand
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
- Toshiaki Hayashi, T. Hideshima, +8 authors Kenneth C. Anderson
- Biology, Medicine
- British journal of haematology
- 1 January 2005
These studies defined the mechanisms whereby IMiDs trigger NK cell‐mediated tumour‐cell lysis, further supporting their therapeutic use in MM. Expand
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
This study investigated the effect of SN50, a cell-permeable specific inhibitor of NF-kappaB nuclear translocation and activity, on MM cells and demonstrated that NF- kappaB activity in MM cells promotes tumor-cell survival and protects against apoptotic stimuli. Expand